Celebrating 20 Years of IGHV Mutation Analysis in CLL
Open Access
- 22 January 2020
- journal article
- review article
- Published by Wiley in HemaSphere
- Vol. 4 (1), e334
- https://doi.org/10.1097/hs9.0000000000000334
Abstract
The division of CLL into 2 broad subsets with highly significant differences in clinical behavior was reported in 2 landmark papers in Blood in 1999.(1,2) The simple analysis of the mutational status of the IGV regions provided both a prognostic indicator and an insight into the cellular origins. Derivation from B cells with very low or no IGV mutations generally leads to a more aggressive disease course than derivation from B cells with higher levels. This finding focused attention on surface Ig (sIg), the major B-cell receptor, and revealed dynamic antigen engagement in vivo as a tumor driver. It has also led to new drugs aimed at components of the intracellular activation cascades. After 20 years, the 2 senior authors of those papers have looked at the history of the observations and at the increasing understanding of the role of sIg in CLL that have emanated from them. As in the past, studies of CLL have provided a link between biology and the clinic, enabling more precise targeting which attacks critical pathways but minimizes side effects.Funding Information
- National Institutes of Health
- CLL Global Research Foundation
- Lauri Strauss Leukemia Foundation
- Cancer Research UK
- Lauri Strauss Leukemia Foundation
This publication has 90 references indexed in Scilit:
- Cellular origin and pathophysiology of chronic lymphocytic leukemiaThe Journal of Experimental Medicine, 2012
- Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemiaNature Genetics, 2012
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemiaNature, 2011
- Innate control of B cell responsesTrends in Immunology, 2011
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- Molecular underpinning of B‐cell anergyImmunological Reviews, 2010
- Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of originBlood, 2010
- Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genesBlood, 2009
- In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemiaBlood, 2009
- Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIABlood, 2008